| P-glycoprotein imaging in temporal lobe epilepsy: In vivo PET experiments with the Pgp substrate [(11) C]-verapamil. | |
| | |
MedLine Citation:
|
PMID: 23134497 Owner: NLM Status: In-Data-Review |
Abstract/OtherAbstract:
|
Overexpression of the multidrug efflux transporter P-glycoprotein (Pgp) at the blood-brain barrier (BBB) is thought to be involved in pharmacoresistance in epilepsy by extruding antiepileptic drugs (AEDs) from their target site. To explore this hypothesis, positron emission tomography (PET) scans were performed with the Pgp substrate-verapamil (VPM) in animal models before and after status epilepticus (SE) and in patients with temporal lobe epilepsy (TLE) and healthy controls. In addition to baseline scans, a second VPM-PET scan was performed after administration of the Pgp inhibitor tariquidar (TQD), showing that VPM uptake at baseline and its increase after Pgp inhibition are reduced in animals following SE compared to baseline, and in refractory TLE relative to healthy controls. In animal models, brain regions with increased Pgp expression (cerebellum, thalamus, and hippocampus) showed reduced influx rate constants from blood to brain, K(1) , of the radiolabeled Pgp substrate relative to control animals. In human studies, preliminary findings are lower K(1) values in refractory compared to seizure-free patients and attenuated increase of K(1) for temporal lobe regions in patients with TLE compared to healthy controls. In summary, there is lower brain uptake of the Pgp substrate VPM in Pgp-rich areas of animals 2 days following SE, as well as lower increase in VPM brain uptake after TQD in patients with refractory TLE compared to healthy controls, supporting the hypothesis of increased cerebral Pgp function following prolonged seizures and as a mechanism contributing to drug resistance in refractory epilepsy. The observation of reduced VPM uptake in refractory compared to seizure-free patients with TLE is consistent with multiple mechanisms affecting Pgp function, including uncontrolled seizures. |
| | |
Authors:
|
Maria Feldmann; Matthias Koepp |
Related Documents
:
|
10694287 - Prevalence rates and an evaluation of reported risk factors for osteonecrosis (avascula... 15283867 - Brain choline concentrations may not be altered in euthymic bipolar disorder patients c... 19577437 - Response to prophylactic lithium in bipolar disorder may be associated with a preservat... 2351777 - Acute polyneuropathy in critically ill patients. 9034427 - Octreotide in hyperinsulinism. 23637697 - Initial 'ttp map-defect' of computed tomography perfusion as a predictor of hemorrhagic... |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Epilepsia Volume: 53 Suppl 6 ISSN: 1528-1167 ISO Abbreviation: Epilepsia Publication Date: 2012 Nov |
Date Detail:
|
Created Date: 2012-11-08 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 2983306R Medline TA: Epilepsia Country: United States |
Other Details:
|
Languages: eng Pagination: 60-3 Citation Subset: IM |
Copyright Information:
|
Wiley Periodicals, Inc. © 2012 International League Against Epilepsy. |
Affiliation:
|
Department of Clinical and Experimental Epilepsy, UCL Institute of Neurology, London, United Kingdom. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Mechanisms underlying blood-brain barrier dysfunction in brain pathology and epileptogenesis: Role o...
Next Document: Why and how to target angiogenesis in focal epilepsies.